Philips launches intelligent 3D imaging in Europe to empower faster stroke care, helping physicians save time, brain, and lives
Demonstrated at LINNC Paris 2025, the company's latest release of SmartCT delivers fast, intelligent 3D imaging in the Angio suite — helping physicians act with greater speed and confidence during a range of critical neurovascular procedures
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the CE-marking of its latest SmartCT image reconstruction solution designed to support faster, more informed decision-making in the treatment of stroke and other neurovascular conditions. Already available in Japan and Canada, SmartCT is now CE-marked and available across Europe. The solution will be showcased at LINNC Paris 2025 (June 2–4), the world's leading interventional neuroradiology congress.
Built for the Philips Azurion neuro biplane system, the latest generation of SmartCT simplifies and accelerates 3D imaging — giving neuro interventionists real-time views of brain tissue, blood vessels, and interventional devices directly in the Angio suite. By removing the need to transfer patients for separate CT imaging, SmartCT helps care teams treat faster, with greater clarity and confidence.
'In stroke care, minutes matter — and confidence is everything,' said Dr. Atul Gupta, Chief Medical Officer Diagnosis & Treatment at Philips. 'With this latest generation of SmartCT for intelligent 3D imaging applications, we're giving neuro interventionalists the imaging tools they need at the exact moment they need them — improving workflow, reducing delays, and ultimately helping to save lives.'
Already used by clinicians at many leading stroke centers worldwide, SmartCT enables a streamlined workflow that reduces procedural complexity and supports timely intervention. This enables physicians to personalize therapy and reduce uncertainty during time-critical procedures like mechanical thrombectomy— a minimally invasive treatment to remove blood clots and restore blood flow to the brain during an ischemic stroke.
'The image quality of the helical cone-beam CT is impressive—it's almost like a conventional CT scan,' said Dr. Shuta Aketa, Director of the Stroke Center at the Osaka International Medical & Science Center. 'This is ideal for emergency procedures, as the image quality meets our needs and helps us work more efficiently.'
Dr. Junji Fukumori, Chief of Neurovascular Intervention of the same hospital added 'Compared to other vendors, Philips SmartCT technology allows for more confident and safe treatment of complex cases.'
SmartCT 3.0 includes: SmartCT Soft Tissue Helical delivers cone-beam CT (CBCT) imaging in as little as 8 seconds. It offers improved image appearance of cerebral soft tissue volumes by optimizing acquisition trajectory and reconstruction.
delivers cone-beam CT (CBCT) imaging in as little as 8 seconds. It offers improved image appearance of cerebral soft tissue volumes by optimizing acquisition trajectory and reconstruction. Motion-compensated soft tissue imaging for restless stroke patients
for restless stroke patients SmartCT Dual Phase Cerebral enables clear visualization of vessel occlusions and collateral blood flow in stroke patients, aided by intuitive acquisition guidance and bolus timing tools.
enables clear visualization of vessel occlusions and collateral blood flow in stroke patients, aided by intuitive acquisition guidance and bolus timing tools. SmartCT Dual Viewer allows physicians to overlay and manipulate two 3D volumes side-by-side at table side, supporting real-time image fusion and enhanced procedural planning without breaking sterility.
At LINNC Paris 2025 (June 2–4, Carrousel du Louvre), Philips will host interactive demos of its latest generation Azurion biplane with SmartCT 3.0 for neuro-endovascular treatments.at Booth #28. For more information about the Philips Image-Guided Therapy System Azurion, visit our website: www.philips.com/biplane.
For further information, please contact:Joost MalthaPhilips External RelationsTel. : +31 6 10558116
E-mail : [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold
On June 5, HSBC upgraded Dr. Reddy's Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. HSBC's updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and gRevlimid. The analysts are waiting for semaglutide to be introduced in Canada, Brazil, and India at the beginning of FY2027, which is a greater leap from their prior hypothesis of a launch only in Canada by Q4 of FY2026. The analysts revised their FY2026 sales figures for Dr. Reddy's Laboratories Limited (NYSE:RDY)'s gRevlimid, noting the growing competition. The adjustment includes a 5.1% decrease in the EPS estimate for FY2026, while the EPS forecast for FY2027 and FY2028 grew by 12% to 13%. According to HSBC analysts, the expected surge in semaglutide sales will strengthen Dr. Reddy's earnings. HSBC assigned a new price target for RDY's American Depositary Receipts (ADR) as well, raising it from $14.44 to $16.90. Dr. Reddy's Laboratories Limited (NYSE:RDY) is a global pharma company based in Hyderabad, India, that makes both branded and generic medicines for a wide range of health conditions. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. While we acknowledge the potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
UBS Upholds Buy Recommendation on Deckers Outdoor (DECK)
On June 5, UBS analysts maintained a Buy rating on Deckers Outdoor Corporation (NYSE:DECK) with a price target of $169. The analysts expect Decker's EPS to top market estimates over the coming year as sales projections increase for its Hoka brand. They also anticipate UGG to keep up its record as a major global casual footwear brand. A customer browsing a retail store, finding the perfect footwear for their casual outfits. The analysts were confident that Deckers Outdoor Corporation (NYSE:DECK) could deliver a low double-digit compound annual sales growth. They forecast that this growth could drive Deckers' forward PE ratio over 20x, compared to the present 16.7x. The $169 price target by UBS reflects a 60% upside for DECK. The stock has plummeted nearly 47% over the last six months, which signals a buying opportunity. After discussions with company management on June 4, the analysts were optimistic about Deckers Outdoor Corporation (NYSE:DECK)'s potential for growth. Despite the market showing caution with reference to the Hoka brand's capacity to sustain robust growth, UBS believes that DECK is perfectly tackling concerns about industry competition, evolving fashion trends, and dependence on Clifton and Bondi franchises. The analysts see double-digit revenue growth for Hoka in the next few years. Deckers Outdoor Corporation (NYSE:DECK) designs and markets premium footwear and apparel worldwide with brands like UGG and HOKA. The company was established in 1973 and is headquartered in Goleta, California. While we acknowledge the potential of DECK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Lemonade Inc (LMND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges
Revenue: Increased 27% year-on-year to $151 million in Q1 2025. In Force Premium (IFP): Grew 27% to just above $1 billion. Customer Count: Increased by 21% to 2.5 million. Premium per Customer: Increased 4% to $396. Annual Retention Rate (ADR): Decreased to 84% from 86% in the prior quarter. Gross Earned Premium: Increased 24% to $234 million. Gross Loss Ratio: 78% for Q1, compared to 79% in Q1 2024. Adjusted Gross Profit: Improved 25% year-on-year. Net Loss: $62 million, or a loss of $0.86 per share. Adjusted EBITDA Loss: $47 million in Q1. Total Cash, Cash Equivalents, and Investments: Approximately $996 million. Growth Spend: $38 million in Q1, nearly double the prior year quarter. Technology Development Expense: Increased 5% to $22 million. General and Administrative (G&A) Expense: Increased 20% to $36 million. Warning! GuruFocus has detected 3 Warning Signs with LMND. Release Date: May 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Lemonade Inc (NYSE:LMND) reported a 27% year-on-year growth in Q1 2025, marking the sixth consecutive quarter of accelerating top-line growth. The company achieved a 25% year-on-year improvement in adjusted gross profit, despite the impact of California wildfires. Lemonade Car's quarter-over-quarter in-force premium (IFP) growth outpaced the rest of the business for the first time, signaling strong momentum. The company is on track to achieve EBITDA breakeven by the end of 2026, with expectations of generating positive adjusted free cash flow in 2025. Lemonade Inc (NYSE:LMND) has successfully leveraged AI to maintain or reduce fixed costs while significantly increasing its book size, demonstrating strong operational efficiency. The California wildfires had a notable impact on Q1 results, contributing 16 percentage points to the gross loss ratio. Annual dollar retention (ADR) decreased to 84%, down from 86% in the prior quarter, partly due to efforts to improve profitability in the home insurance book. The gross loss ratio for Q1 was 78%, slightly higher than the previous year's 79%, indicating ongoing challenges in managing claims costs. Operating expenses, excluding loss and loss adjustment expense, increased by 29% year-on-year, driven by growth spend and the impact of the FAIR plan assessment. Net loss for Q1 was $62 million, or $0.86 per share, compared to a net loss of $47 million or $0.67 per share in the prior year, reflecting ongoing financial challenges. Q: Can you elaborate on the timeline for reaching EBITDA profitability and what levers will drive this? A: Daniel Schreiber, CEO, explained that Lemonade aims to achieve adjusted EBITDA breakeven by the end of 2026, with 2027 being the first full year of positive adjusted EBITDA. The company expects gross profit to grow faster than fixed costs, driven by AI efficiencies, bringing them closer to profitability. Q: What impact did the California wildfires have on gross profit, and how are tariffs affecting your full-year guidance? A: Tim Bixby, CFO, noted that the California wildfires had a $44 million gross impact, aligning with prior estimates. The tariff impact is expected to be modest, with single-digit percentage effects on claims. Lemonade is comfortable with its full-year guidance, assuming a modest headwind from tariffs. Q: How is Lemonade's Car business performing, and what are the plans for geographic expansion? A: Daniel Schreiber, CEO, highlighted that Lemonade Car is growing faster than the rest of the business, with a focus on refining the product before expanding geographically. The company is currently available to 40% of the U.S. market and plans to expand further once the product is optimized. Q: How is AI impacting Lemonade's competitive position in the insurance industry? A: Daniel Schreiber, CEO, emphasized that Lemonade's AI capabilities allow for better data utilization and risk assessment compared to traditional insurers. The company's digital infrastructure enables it to connect data points effectively, providing a competitive advantage in pricing and customer acquisition. Q: What percentage of new car sales are cross-sales from existing Lemonade customers? A: Tim Bixby, CFO, stated that about half of new car sales are cross-sales from existing customers, up from a third previously. This trend is expected to continue, leveraging Lemonade's existing customer base for more efficient growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
